Streetbeat News

GRPH

Graphite Bio Inc

Employees

119

Industry

Research and Development in Biotechnology

graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process of homology directed repair (hdr) and targeted dna integration to precisely repair genetic defects at their source. graphite bio is leveraging its differentiated platform to advance a portfolio of transformative genetic treatments with potential for saving and dramatically improving patients’ lives

Open

3.20

Mkt cap

185M

Volume

299K

High

3.23

P/E Ratio

-0.21

52-wk high

29.82

Low

3.05

Div yield

0.32

52-wk low

3.05

In Wednesday's pre-market session, several healthcare stocks showed significant movement. Chemomab Therapeutics, Heart Test Laboratories, Kinnate Biopharma, Heron Therapeutics, Solid Biosciences, and Cormedix experienced gains, with Chemomab leading at a 65.6% increase. On the losing side, Graphite Bio, SILO Pharma, GT Biopharma, Tivic Health Systems, Aditxt, and Varex Imaging saw their stock prices fall, with Graphite Bio dropping by 14.6%. The movements were largely attributed to recent Q3 and Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 1:06 pm

LENZ Therapeutics and Graphite Bio have entered into a definitive merger agreement to combine in an all-stock transaction. The merged entity will trade on Nasdaq under the ticker 'LENZ'. The combined company is anticipated to have around $225 million in cash or cash equivalents, including proceeds from concurrent PIPE financing.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 12:04 pm

Graphite Bio has appointed Kimberlee C. Drapkin as President and CEO, and as Principal Executive, Financial and Accounting Officer, effective from August 21, 2023, according to a filing.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2023 | 8:40 pm

Graphite Bio has announced a reduction in its workforce by approximately 70% and is exploring strategic alternatives. Additionally, Josh Lehrer has departed as CEO effective as of August 21, 2023, according to a filing.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2023 | 8:35 pm

Graphite Bio announced the departure of CFO Alethia Young, who will step down to pursue other opportunities. She will remain with the company until June 30, 2023, to ensure a smooth transition.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 11:03 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.